Le Lézard
Classified in: Health, Science and technology, Business
Subjects: JVN, TRI

Bluefield Innovations Pursues Broadly Applicable Cancer Target



NEW YORK and BALTIMORE, Jan. 4, 2018 /PRNewswire/ -- Bluefield Innovations, a collaboration between Deerfield Management and The Johns Hopkins University to catalyze early stage therapeutic development, announced today the acceptance and funding of its first project. The target, the enzyme RNA polymerase I (Pol I), is implicated in many forms of cancer.

Originating in the lab of Dr. Marikki Laiho, the Willard and Lillian Hackerman Professor of Radiation Oncology and director of the Division of Molecular Radiation Sciences at the Johns Hopkins University School of Medicine, the discovery illustrates how cancer cells disproportionately rely on the Pol I cellular pathway when compared to normal cells. Dr. Laiho's research indicates that interfering with this pathway kills cancer cells while causing little harm to normal cells. The acceptance of this project comes just two months after the launch of Bluefield Innovations.

"We are excited to accept Dr. Laiho's project into Bluefield Innovations and show our commitment to the goal of advancing promising research projects," says James Flynn, Managing Partner at Deerfield Management.

Bluefield will provide scientific, financial and operational support to Dr. Laiho's research, enabling her team to identify the clinical lead molecule and to move that candidate toward human clinical trials. Ultimately, this support could lead to the development of a first-in-class small molecule drug.

"I truly appreciate the opportunity to align with a collaborator that shares the same mindset and goals surrounding early stage research targets," Dr. Laiho says. "Bluefield understands that new targets and first-in-class molecules require a higher level of due diligence and with that, they provide the expertise to support the extensive ground work required for the IND process."

A joint steering committee consisting of representatives from Deerfield and Johns Hopkins selected Dr. Laiho's research to receive the first round of support from Bluefield. The initial five-year term of Bluefield Innovations will provide support and funding to approximately a dozen Johns Hopkins faculty and researchers. A call for applications will take place in the first quarter of 2018.

"Bluefield Innovations provides a valuable avenue for Johns Hopkins researchers to unleash the potential of their promising work," says Dr. William Nelson, professor of oncology and director of the Johns Hopkins Sidney Kimmel Cancer Center. "Dr. Laiho's research may prove to be a transformational cancer treatment. We're excited that Bluefield has provided her an opportunity to accelerate its development and commercialization."

About Bluefield Innovations

Bluefield Innovations is an innovative collaboration between The Johns Hopkins University and Deerfield Management that is dedicated to navigating the complexities of scientific advancement from concept to commercialization. Funded by Deerfield Management, Bluefield Innovations is providing up to $65 million over five years to support the commercialization of early stage therapeutic research at Johns Hopkins.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com.

Contacts
Deerfield Management Company
Karen Heidelberger, 212-551-1600
karenh@deerfield.com

SOURCE Deerfield Management Company


These press releases may also interest you

at 22:00
PASADENA, Calif., Aug. 21, 2018 /PRNewswire-PRWeb/ -- An August 7 article in The Economic Times discusses research by the WHO (World Health Organization) which found that eating processed starch seemed to increase the risk of tooth decay while,...

at 22:00
Asia's largest exhibition and conference dedicated to the Medical Device Design and Manufacturing industry, "Medtec Japan 2019" will be held in Tokyo from 18th Mon - 20th Wed March 2019. Over 560 exhibitors from some 25...

at 19:30
Today, the Canadian Medical Association (CMA) presented its 2018 awards as part of its annual recognition of outstanding individuals who have made an exceptional contribution to medicine and the health care system. "Taking a moment to highlight and...

at 19:01
Ascensia Diabetes Care today announced the launch of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in Australia. The easy-to-use CONTOUR®NEXT ONE smart meter seamlessly connects to the CONTOUR®DIABETES app via Bluetooth® connectivity,...

at 18:36
Today, an article from The Children's Hospital of Philadelphia (CHOP) was published in The Journal of the American Medical Association regarding a study testing consumer pulse oximeter baby monitors' accuracy, namely the Owlet Smart Sock and the Baby...

at 18:16
Roche (SIX: RO, ROG; OTCQX: RHHBY) today commended the United States Preventive Services Task Force (USPSTF) for issuing new cervical cancer screening guidelines that use scientific evidence as the basis for recommending, for the first time, human...




News published on 4 january 2018 at 08:15 and distributed by: